secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001867096-24-000157
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Biopharma Q2 revenue $48.1M (+26% YoY); raises FY revenue guidance to $190-200M; appoints John Shannon CEO
--------------------------------------------------------------------------------

- Total revenue of $48.1M (+26% YoY); product revenue record $46.5M.
- Recorlev revenue surged 86% YoY to $13.3M; Gvoke up 28% to $20.0M; Keveyis down 7% to $13.1M due to generics.
- Tightens FY2024 revenue guidance to $190-200M (from $175-200M) and year-end cash to $60-75M.
- John Shannon appointed CEO and Kevin McCulloch promoted to President & COO as part of succession plan.
- Net loss of $15.0M ($0.10 per share); cash and equivalents $77.6M at June 30, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709624000157/0001867096-24-000157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709624000157/xers-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001867096-24-000157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer